Status:
COMPLETED
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
Lead Sponsor:
Northwell Health
Conditions:
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Ziprasidone is a newer drug intended for the treatment of the symptoms of schizophrenia. This new drug may have an added benefit of being able to help with some of the difficulties in problem solving ...
Detailed Description
Typical neuroleptics (i.e., haloperidol, chlorpromazine) are effective at ameliorating the positive psychotic symptoms of schizophrenia but are less efficacious in the treatment of negative symptoms, ...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder
- Ages 18 - 50
- Ability to provide written informed consent
- Brief Psychiatric Rating Scale (BPRS) total score \> 40 and Clinical Global Impressions (CGI) \> 4 (moderately ill) and/or intolerant to current antipsychotic drug treatment
Exclusion
- History of prior treatment with ziprasidone
- History of medical condition that contraindicates ziprasidone treatment
- Treatment with depot antipsychotic medication in past 3 months
- Current diagnosis of alcohol or psychoactive substance dependence
- Impaired ability to provide written informed consent
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00225498
Start Date
June 1 2002
End Date
October 1 2008
Last Update
September 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004